Last Updated on October 10, 2024 by The Health Master
A panel of outside advisers to the US health regulator will meet late next month to discuss whether to authorise Merck & Co’s experimental C-19 anti-viral drug, the agency said yesterday.
The US Food and Drug Administration’s (USFDA’s) panel will meet on 30th November, 2021 to discuss the safety and effectiveness of the drug, Molnupiravir, for the treatment of mild-to-moderate C-19 in adults who have tested positive and are at high risk for progression to severe illness.
The FDA typically follows the advice of its experts but is not bound to do so.
Merck earlier this week said it filed for the US Emergency Use Authorisation (EUA) for Molnupiravir, which it is developing with partner Ridgeback Biotherapeutics. The drug would become the first oral anti-viral medication for C-19, if cleared by the agency.
Pfizer and Roche Holding AG are also racing to develop an easy-to-administer anti-viral pill for the disease.
Merck’s treatment cut the rate of hospitalisation and death by 50 per cent in a trial of mild-to-moderately ill patients who had at least one risk factor for the disease, according to data released earlier.
The company has a contract with the US government to supply 1.7 million courses at a price of $700 per course. The drugmaker also recently signed deals with Malaysia and Singapore for supply of the drug.
CDSCO issues alert on these insulin pumps: Medical Devices
IPC flags safety alert against Dimethyl Fumarate & Cefazolin
FDCA Commissioner inaugurates Pharma Research and Analytical Lab
IOL Chemicals & Pharma gets nod for 2 APIs
Govt notifies MTP Rules 2021 for abortion up to 24 weeks
Latest Notifications: Homoeopathic
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
